Axsome Therapeutics and Veeva Systems Partner to Build Axsome’s Digital-Centric Commercialization™ Platform
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, and Veeva Systems (NYSE: VEEV), today announced a strategic partnership to augment the build of Axsome’s Digital-Centric Commercialization (DCC™) platform. Veeva is the leader in cloud solutions for the global life sciences industry.
The partnership with Veeva is part of the continuing build of Axsome’s DCC platform in preparation for the potential launch of two differentiated CNS investigational medicines, AXS-05 for depression and AXS-07 for migraine, anticipated next year. The Axsome DCC platform is a proprietary approach to commercialization that incorporates specialized digital tools, proprietary data and analytics, integrated systems, and an intelligent operating model. Through this digital platform, Axsome aims to optimize physician and patient engagements, enhance engagement quality, and increase the effectiveness of promotional efforts as compared to traditional approaches.
The Axsome DCC platform will utilize all Veeva Commercial Cloud products and services, including: multichannel Veeva CRM as the technology foundation for engagement of customers through preferred digital and personal channels; MyVeeva for Doctors mobile application for healthcare professionals (HCPs) that will allow efficient and compliant real-time messaging between HCPs and Axsome; and Veeva Data Cloud which will provide longitudinal data to power an efficient, targeted launch.
As part of the strategic partnership, Axsome will also have early access to new digital technologies developed by Veeva, and Axsome will help shape Veeva’s product direction. This access will increase the scope of digital tools available to Axsome. In addition, Veeva’s Business Consulting team will provide deep domain expertise and the most complete, industrywide engagement data and insights to support Axsome’s launch strategy.
“Veeva is an ideal partner for Axsome as they share our commitment to innovation and passion for improving patient care,” said Herriot Tabuteau, M.D., chief executive officer of Axsome. “This partnership provides us a specialized platform of technology, data, and business consulting to drive our Digital-Centric Commercialization approach for more effective and capital efficient commercial execution.”
“Axsome’s Digital-Centric Commercialization strategy would represent a significant shift for the pharmaceutical industry. We are pleased to partner closely with Axsome to help shape and execute their innovative launch plans,” said Peter Gassner, founder and CEO at Veeva. “We are committed to moving the industry forward by combining the best in technology, data, and business consulting.”
About Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. For the many people facing unsatisfactory treatments for CNS disorders, Axsome accelerates the invention and adoption of life-changing medicines. Axsome’s core CNS product candidate portfolio includes five clinical-stage candidates, AXS-05, AXS-07, AXS-09, AXS-12, and AXS-14. AXS-05 is being developed for major depressive disorder (MDD), Alzheimer’s disease (AD) agitation, and as a treatment for smoking cessation. AXS-07 is being developed for the acute treatment of migraine. AXS-12 is being developed for the treatment of narcolepsy. AXS-14 is being developed for fibromyalgia. AXS-05, AXS-07, AXS-09, AXS-12, and AXS-14 are investigational drug products not approved by the FDA. For more information, please visit the Axsome’s website at axsome.com. Axsome may occasionally disseminate material, nonpublic information on the company website.
About Veeva Systems
Veeva Systems Inc. is the leader in cloud solutions—including data, software, and services—for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 900 customers, ranging from the world’s largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com/eu.
Forward Looking Statements Regarding Axsome Therapeutics, Inc.
Certain matters discussed in this press release are “forward-looking statements”. Axsome may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Axsome’s statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the success, timing and cost of Axsome’s ongoing clinical trials and anticipated clinical trials for Axsome’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including Axsome’s ability to fully fund our disclosed clinical trials, which assumes no material changes to Axsome’s currently projected expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of Axsome’s ongoing clinical trials, and the number or type of studies or nature of results necessary to support the filing of a new drug application (“NDA”) for any of Axsome’s current product candidates; Axsome’s ability to fund additional clinical trials to continue the advancement of Axsome’s product candidates; the timing of and Axsome’s ability to obtain and maintain U.S. Food and Drug Administration (“FDA”) or other regulatory authority approval of, or other action with respect to, Axsome’s product candidates (including, but not limited to, with or without a special protocol assessment); the potential for Axsome’s clinical trials to provide a basis for accelerated approval of Axsome’s product candidates for the treatment of several indications and accelerate their development timelines and commercial paths to patients (including, but not limited to, with or without a breakthrough therapy designation); Axsome’s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to Axsome, if at all; the successful implementation of Axsome’s research and development programs and collaborations; the success of Axsome’s license agreements; the acceptance by the market of Axsome’s product candidates, if approved; Axsome’s anticipated capital requirements, including Axsome’s anticipated cash runway and Axsome’s ability to fund Axsome’s commercial launch, which assumes product approval; unforeseen circumstances or other disruptions to normal business operations arising from or related to COVID-19; and other factors, including general economic conditions and regulatory developments, not within Axsome’s control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and Axsome undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance.
Forward Looking Statements Regarding Veeva Systems Inc.
This release contains forward-looking statements, including regarding the partnership with Axsome and its potential benefits, the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions, particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in Veeva’s filing on Form 10-Q for the period ended July 31, 2020. This is available on Veeva’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.
® 2020 Veeva Systems Inc. All rights reserved. Veeva and the Veeva logo are trademarks of Veeva Systems Inc.
Veeva Systems Inc. owns other registered and unregistered trademarks.
Axsome Therapeutics, Inc.
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rand Technology Appoints Key Executives Across Global Regions4.12.2020 00:30:00 CET | Press release
Rand Technology (Rand) has appointed Kim Fix, Chief Operating Officer (COO), Americas & Europe; Frederick Fu, President and Managing Director, Asia-Pacific (APAC); Nami Mokri, Vice President, Sales & Sourcing, APAC; Kevin Sheehan, Chief Information Officer (CIO); and Jennifer Strawn, Director, Sourcing & Procurement, Americas & Europe. Kim Fix, Global Vice President, QA & Operations, has been appointed to COO, Americas & Europe. Kim will lead Rand’s sales and sourcing teams’ operations across the Americas and Europe and oversee global compliance, quality assurance, and operations. Kim has been integral to Rand’s preferred status with its business partners and multi-site ISO, OHSAS, ANSI ESD, and R2 certifications. Frederick Fu joined Rand as President and Managing Director, APAC. He previously served as Avnet’s President of APAC. He has been fundamental to Rand’s efficacy, growth, strategy, and success in the APAC region. Nami Mokri was appointed Vice President, Sales & Sourcing, APAC.
Kalray Joins MLCommons as Founding Member3.12.2020 18:30:00 CET | Press release
Kalray (Euronext Growth Paris: FR0010722819 – ALKAL) (Paris:ALKAL), a pioneer in processors for new intelligent systems, today announced it has joined MLCommons as founding member. MLCommons is a not for profit, engineering consortium founded by 30+ global technology and academic leaders in AI and Machine Learning to accelerate machine learning innovation and broaden access to this critical technology for the public good. Initially formed as MLPerf, MLCommons boasts a founding board that includes representatives from Alibaba, Facebook AI, Google, Intel, NVIDIA and Professor Vijay Janapa Reddi of Harvard University with the objective to deliver industry-wide benchmarks, best practices and datasets to speed computer vision, natural language processing, and speech recognition development for all. “MLCommons has a clear mission - accelerate Machine Learning innovation to ‘raise all boats’ and increase its positive impact on society” said Peter Mattson, President of MLCommons. “We are excit
Hyperloop Transportation Technologies Accelerates with 100 Engineers from World Leading Firm Altran3.12.2020 17:40:00 CET | Press release
Hyperloop Transportation Technologies (HyperloopTT) announced today an agreement with world-leading engineering and R&D services provider Altran, part of the Capgemini Group. The agreement includes one hundred Altran engineers to accelerate the development of commercialized passenger hyperloop systems at the HyperloopTT facility in Toulouse, France, the Aerospace Valley of Europe. HyperloopTT’s European R&D Center is the home of the world’s only full-scale hyperloop system, which has been undergoing testing and optimization since 2019. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201203005174/en/ HyperloopTT's full-scale test system in Toulouse, France (Photo: Business Wire) The agreement advances HyperloopTT’s capabilities in a lean way, negotiated within HyperloopTT’s hybrid collaborative framework. The announcement comes after recent commitments from both the European Union and the United States, emphasizing the develop
Dan Bilzerian Joins Team GGPoker & Celebrates With $100,000 Birthday Freeroll3.12.2020 17:00:00 CET | Press release
GGPoker today announces that Dan Bilzerian has joined Team GGPoker as a brand ambassador. One of the world’s most recognizable poker players and social media influencers, with over 32 million followers on Instagram, “Blitz” will represent GGPoker live and online. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201203005724/en/ Dan Bilzerian, GGPoker's newest brand ambassador. (Photo: Business Wire) To celebrate the news, the online poker room will host a special 40th birthday party for the ‘King of Instagram’ on December 7 in the form of a $100,000 Birthday Freeroll poker tournament. This free-to-enter poker game is open to all new GGPoker players that sign up using code BLITZ40 and deposit $10 or more. What: Dan’s $100,000 Birthday Freeroll When: Monday, December 7 at 17:00 UTC How To Enter: Sign up using code BLITZ40, deposit at least $10 and use your ticket to register for the freeroll tournament Tournament Prize Pool: $10
Odense Investor Summit Introduces Investors to 15 Promising Robot Companies in Europe’s Robot Capital3.12.2020 16:47:00 CET | Press release
In just five years, robotic start-ups based in Odense, Denmark – the robot capital of Europe – have attracted more than 976 million USD. This year, the local Danish entrepreneurs will be joined by companies from the RobotUnion Super Stars; finalists from the pan-European robot acceleration program. The event is being sponsored by Vækstfonden, the Danish State’s investment fund, with the objective of making matches between leading Danish entrepreneurs seeking capital backing, and top international investors on the hunt for the next “golden goose” in the world of robotics. On December 9th, a carefully selected field of robot enterprises seeking capital will be presenting their ground-breaking automation solutions for a broad spectrum of industries at this year’s Odense Investor Summit. The 2020 summit is being held as a virtual event to involve participants from all parts of Europe and provide access to a new audience while still observing the prevailing COVID-19 restrictions. In additio
IEEE Launches 802.3™ Beyond 400Gb/s Ethernet Study Group to Define Next High Speed Threshold for Ethernet Data Rate3.12.2020 16:30:00 CET | Press release
IEEE, the world's largest technical professional organization dedicated to advancing technology for humanity, and IEEE Standards Association (IEEE SA) today announced the formation of a study group within the IEEE 802.3™ Ethernet Working Group. With bandwidth demand growing across all areas of Ethernet connectivity globally, the IEEE 802.3 Beyond 400Gb/s Ethernet Study Group will explore initiating a new IEEE project that would standardize capabilities exceeding today’s maximum data rate of 400 Gigabit per second (Gb/s) for https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fstandards.ieee.org%2Fstandard%2F802_3-2018.html%3Futm_source%3Dbusinesswire%26utm_medium%3Dpr%26utm_campaign%3Dworking-group-2020%26utm_content%3D802&esheet=52341781&newsitemid=20201203005124&lan=en-US&anchor=IEEE+802.3%2C+IEEE+Standard+for+Ethernet&index=2&md5=214f246922adc89c9023ea7f9b810359 IEEE 802.3, IEEE Standard for Ethernet. The publicly available IEEE 802.3™ Ethernet Bandwidth Assessment (BWA
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom